Julie Gerberding - Merck President

Dr. Julie Louise Gerberding, M.D. is Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy and Population Health of Merck Co., Inc. In this newly created Executive Committee position, Gerberding, who most recently served as president of Merck Vaccines, will be responsible for Mercks global public policy, corporate responsibility and communications functions, as well as the Merck Foundation and the Merck for Mothers program. Gerberding will also lead new partnership initiatives that accelerate Mercks ability to contribute to improved population health, a measure of impact that is increasingly valued by governments and other global health organizations. Gerberding joined Merck as president of Merck Vaccines in January 2010. Since then, Mercks vaccines are reaching more people than ever, and Merck became the global leader in the vaccine market based on sales. In addition, the Sanofi Pasteur MSD joint venture in Europe, Mercks European vaccine business for which Gerberding is the Board cochair, has improved in both population reach and financial performance. She also helped lead the successful launch in India of the Merck Wellcome Trust nonprofit joint venture for vaccine development, the MSD Wellcome Trust Hilleman Laboratories. Prior to joining Merck, Gerberding served as director of the U.S. Centers for Disease Control and Prevention from 20022009 and before that served as director of the Division of Healthcare Quality Promotion. Before joining the CDC, Gerberding was a tenured faculty member in Infectious Diseases at the University of California at San Francisco . She continues as an Adjunct Associate Clinical Professor of Medicine at UCSF. since 2016.